文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Immunologic assessment of the impact of SARS-CoV-2 vaccine booster doses on humoral immunity: a cross-sectional study in morocco.

作者信息

Abounouh Karima, Tajudeen Raji, Majidi Hind, Redwane Soad, Laazaazia Oumaima, Aqillouch Safaa, Ouma Ahmed E Ogwell, Abdulaziz Mohammed, Aragaw Merawi, Fallah Mosoka Papa, Sembuche Senga, Batcho Serge, Kabwe Patrick, Gonese Elizabeth, Ainahi Abdelhakim, Sarih M'hammed, Kaseya Jean, Maaroufi Abderrahmane, Ezzikouri Sayeh

机构信息

Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, 1 Place Louis Pasteur, Casablanca, 20360, Morocco.

Africa Centres for Disease Control and Prevention (Africa CDC), African Union, Addis Ababa, Ethiopia.

出版信息

BMC Infect Dis. 2024 Dec 28;24(1):1470. doi: 10.1186/s12879-024-10345-9.

DOI:10.1186/s12879-024-10345-9
PMID:39732651
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11682633/
Abstract

To assess the impact of the SARS-CoV-2 booster dose on the immune response against COVID-19, we conducted a cross-sectional study in the Casablanca-Settat region of Morocco. The study included 2,802 participants from 16 provinces, all of whom had received three doses of a SARS-CoV-2 vaccine. IgG antibodies targeting the S1 RBD subunit of the SARS-CoV-2 spike protein were quantified using the SARS-CoV-2 IgG II Quant assay and measured on the Abbott Architect i2000SR instrument. Adjusted seroprevalence of anti-RBD antibodies showed that participants who received two doses of ChAdOx1-S followed by a BBIBP-CorV booster had a seroprevalence rate of 99.68% (95% CI: 99.39-99.83%), while those who received a BNT162b2 booster had a rate of 99.67% (95% CI: 99.38-99.82%). Both rates were higher than those observed with other vaccination regimens. The evaluation of booster dose effects revealed significant differences in anti-RBD antibody levels across various vaccination regimens: two doses of BBIBP-CorV compared to three doses of BBIBP-CorV (P < 0.0001), two doses of BNT162b2 versus three doses of BNT162b2 (P = 0.023), two doses of ChAdOx1-S versus two doses of ChAdOx1-S with a BNT162b2 booster (P = 0.023), and two doses of BBIBP-CorV versus two doses of BBIBP-CorV with a BNT162b2 booster (P < 0.0001). However, no significant difference was found between two doses of ChAdOx1-S and three doses of ChAdOx1-S (P = 0.23). Participants with prior SARS-CoV-2 exposure who received two doses of ChAdOx1-S followed by either a BBIBP-CorV or BNT162b2 booster showed higher levels of anti-RBD IgG antibodies (P = 0.042 and P = 0.001, respectively). Interestingly, individuals with comorbidities who received the BNT162b2 booster dose exhibited a significantly stronger humoral response (P < 0.05). In conclusion, our findings highlight the effectiveness of the BNT162b2 booster dose in eliciting a strong immune response. The high seroprevalence rates achieved with both BNT162b2 and BBIBP-CorV boosters reflect the country's robust vaccination strategy.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/d2027035d009/12879_2024_10345_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/bdfec925452e/12879_2024_10345_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/56fac08469de/12879_2024_10345_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/e017173e6c59/12879_2024_10345_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/d0c1432ac13e/12879_2024_10345_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/e86f602c9681/12879_2024_10345_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/8aee07c815e3/12879_2024_10345_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/5257ba1e713e/12879_2024_10345_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/d2027035d009/12879_2024_10345_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/bdfec925452e/12879_2024_10345_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/56fac08469de/12879_2024_10345_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/e017173e6c59/12879_2024_10345_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/d0c1432ac13e/12879_2024_10345_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/e86f602c9681/12879_2024_10345_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/8aee07c815e3/12879_2024_10345_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/5257ba1e713e/12879_2024_10345_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1839/11682633/d2027035d009/12879_2024_10345_Fig8_HTML.jpg

相似文献

[1]
Immunologic assessment of the impact of SARS-CoV-2 vaccine booster doses on humoral immunity: a cross-sectional study in morocco.

BMC Infect Dis. 2024-12-28

[2]
Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.

Sci Rep. 2024-4-3

[3]
The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series.

Asian Pac J Allergy Immunol. 2024-9

[4]
Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study.

Front Immunol. 2024

[5]
Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia.

PLoS One. 2022

[6]
Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.

Influenza Other Respir Viruses. 2024-5

[7]
Comparable and sustained levels of S1-RBD-IgG and S1-RBD-IgA in BNT162b2 homologous and CoronaVac-BNT162b2 heterologous booster vaccination: A 22-month prospective study in Malaysia.

Vaccine. 2024-12-2

[8]
Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico.

Viruses. 2024-4-1

[9]
Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.

Microbiol Spectr. 2021-12-22

[10]
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.

J Infect. 2025-2

本文引用的文献

[1]
Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.

Sci Rep. 2024-4-3

[2]
Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status - United States, April 2021-September 2022.

MMWR Morb Mortal Wkly Rep. 2023-6-2

[3]
Mix-and-match COVID-19 vaccines trigger high antibody response after the third dose vaccine in Moroccan health care workers.

Vaccine X. 2023-8

[4]
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses.

Nat Rev Immunol. 2023-3

[5]
Estimate of anti-SARS-CoV-2 spike IgG antibodies prevalence among Iranian population based on blood donations: A serial cross-sectional study during the third wave of the pandemic.

Transfus Clin Biol. 2023-2

[6]
Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.

BMC Public Health. 2022-8-20

[7]
Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece.

Vaccines (Basel). 2022-5-30

[8]
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.

N Engl J Med. 2022-4-28

[9]
Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies.

Vaccine. 2022-5-3

[10]
Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers.

Vaccines (Basel). 2022-3-18

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索